These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3480917)

  • 1. Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients.
    Ruibal A; Genollá J; Rosell M; Gris JM; Colomer R
    Int J Biol Markers; 1986; 1(3):159-60. PubMed ID: 3480917
    [No Abstract]   [Full Text] [Related]  

  • 2. CA 15.3 as a tumour marker in breast cancer.
    Schmidt-Rhode P; Schulz KD; Sturm G; Raab-Frick A; Prinz H
    Int J Biol Markers; 1987; 2(3):135-42. PubMed ID: 3482660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of a cancer antigen, CA 15-3, associated with breast cancer. (I) Modification of its method and reference values].
    Sakurabayashi I; Kawai T; Kawaguchi R; Yonezawa M
    Rinsho Byori; 1986 Jan; 34(1):53-8. PubMed ID: 3457966
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum CA 15.3 in women with non-tumor breast pathologies. Initial results].
    Ruibal A; Colomer R; Gris JM; Genollá J
    Med Clin (Barc); 1986 Sep; 87(9):393-4. PubMed ID: 3467152
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum BCM levels in patients with non-tumoral pathologies: a value of 25 U/ml can be used as threshold for tumoral activity.
    Allende MT; Vizoso F; Fueyo A; Roiz MC; Lennartz L; Ruibal A
    Int J Biol Markers; 1990; 5(1):50-1. PubMed ID: 2230353
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA-125 monitoring during chemotherapy for ovarian cancer.
    Martoni A; Bellucco A; Marabini A; Orlandi C; Platé L; Bianchi D; Pannuti F
    Int J Biol Markers; 1986; 1(3):121-8. PubMed ID: 3480916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of CA125 and its assessment with an enzyme immunoassay.
    Shi QY; Sakawaki T; Kasamatsu T; Ohkura H
    Asia Oceania J Obstet Gynaecol; 1987 Sep; 13(3):325-33. PubMed ID: 3325003
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
    Yenisey C; Güner G
    Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
    [No Abstract]   [Full Text] [Related]  

  • 10. Localisation of Ca and HMFG2 antigens in breast tissue by immunoperoxidase, immunofluorescence, and immunoelectron microscopy.
    Beckford U; Barbatis C; Beesley JE; Linsell JC; Chantler SM
    J Clin Pathol; 1985 May; 38(5):512-20. PubMed ID: 3889068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunohistochemical evaluation of several tumor markers (CEA, ferritin, Ca) and their correlation with estro-progestin receptor state in neoplasms].
    Forti E; Wolf D; Melia M
    Pathologica; 1985; 77(1049):241-9. PubMed ID: 3913892
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer.
    Sacks NP; Stacker SA; Thompson CH; Collins JP; Russell IS; Sullivan JA; McKenzie IF
    Br J Cancer; 1987 Dec; 56(6):820-4. PubMed ID: 2449238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA-15.3, TPA and MCA as markers for breast cancer.
    Barak M; Steiner M; Finkel B; Abrahamson J; Antal S; Gruener N
    Eur J Cancer; 1990; 26(5):577-80. PubMed ID: 2144745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Ca antigen in sera from normal individuals and patients with benign and malignant breast disease.
    Goodall AB; Evans CJ; Trivedi D; Coombes RC; Chantler SM
    Br J Cancer; 1985 Aug; 52(2):177-82. PubMed ID: 2411281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of CA-125 in patients with endometriosis.
    Giudice LC; Jacobs AJ; Bell CE; Lippmann L
    Gynecol Oncol; 1986 Oct; 25(2):256-8. PubMed ID: 3463522
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor markers in mammary carcinoma. An evaluation of carcinoembryonic antigen, placental alkaline phosphatase, pseudouridine and CA-50.
    Rasmuson T; Björk GR; Damber L; Jacobsson L; Jeppsson A; Stigbrand T; Westman G
    Acta Oncol; 1987; 26(4):261-7. PubMed ID: 3479987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating CA 15.3 levels in breast cancer. Our present experience.
    Colomer R; Ruibal A; Navarro M; Encabo G; Sole LA; Salvador L
    Int J Biol Markers; 1986; 1(2):89-92. PubMed ID: 3480915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tissue polypeptide antigen in breast cancer].
    Nomizu T; Watanabe I; Endo S
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2287-95. PubMed ID: 6085339
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical evaluation of a cancer antigen, CA 125, associated with ovarian cancer. I. Technical investigation and the reference value].
    Sakurabayashi I; Kawai T; Suzuki M; Tamada T; Sato K; Yonezawa M
    Rinsho Byori; 1984 Dec; 32(12):1345-9. PubMed ID: 6597875
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.
    Miserez AR; Günes I; Müller-Brand J; Walther E; Fridrich R; Mäcke H
    Eur J Cancer; 1991; 27(2):126-31. PubMed ID: 1827273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.